Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07278986 · ClinicalTrials.gov registry record · Early Phase 1
CYTALUX for Intraoperative Imaging of Patients With Endometrial Cancer
A Early Phase 1 study of Endometrial Cancer and Near Infrared Fluorescence Imaging, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
- 2
- Study locations
NCT07278986: Recruiting Early Phase 1 study of Endometrial Cancer and Near Infrared Fluorescence Imaging, sponsored by Abramson Cancer Center at Penn Medicine.
NCT07278986 is a Early Phase 1 study of Endometrial Cancer and Near Infrared Fluorescence Imaging that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 10 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07278986, a Early Phase 1 study of Endometrial Cancer and Near Infrared Fluorescence Imaging, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
- 2
- Study locations
Study Summary
The research study is being done to assess the safety and ability of an investigational drug called CYTALUX (pafolacianine) and a special camera system for the detection of cancer in patients undergoing surgical resection for endometrial cancer.
Primary Outcome
The primary efficacy endpoint is the sensitivity of CYTALUX with NIR imaging for detection of malignant lesions. Sensitivity is defined as the proportion of fluorescent light positive lesions that are histologically confirmed to be cancer relative to the total number of lesions confirmed to be cancer. Sensitivity = (True Positive)/(True Positive + False Negative)
Conditions Studied
Interventions
- DRUG CYTALUX™ (pafolacianine)
- DEVICE 1788 4K Camera System with Advanced Imaging Modality
Study Locations (2)
Pennsylvania
- Abramson Cancer Center at Penn Medicine - Philadelphia
- University of Pennsylvania Gynecologic Oncology Department - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-10-18 |
| Est. Completion | 2029-02 |
| Phase | Early Phase 1 |
What NCT07278986 shows while recruiting
NCT07278986 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (98% lower).
The record links to 4 conditions, with Endometrial Cancer appearing as the primary indexed condition, and to 2 interventions - of which CYTALUX™ (pafolacianine) is the first listed.
NCT07278986 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07278986 about?
NCT07278986 is a clinical study titled "CYTALUX for Intraoperative Imaging of Patients With Endometrial Cancer". The research study is being done to assess the safety and ability of an investigational drug called CYTALUX (pafolacianine) and a special camera system for the detection of cancer in patients undergoing surgical resection for endometrial cancer.
What is the current status of trial NCT07278986?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2025-10-18. Estimated completion is 2029-02.
What conditions does trial NCT07278986 study?
This clinical trial studies the following conditions: Endometrial Cancer, Near Infrared Fluorescence Imaging, CYTALUX (Pafolacianine) Injection, Planned Diagnostic Laparoscopies.
What interventions are being tested in trial NCT07278986?
The interventions under investigation include: CYTALUX™ (pafolacianine) (DRUG), 1788 4K Camera System with Advanced Imaging Modality (DEVICE).
Who is sponsoring clinical trial NCT07278986?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07278986 being conducted?
This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07278986's enrollment target sits among peer trials
10 177th of 181 higher than 2 of 181 other Endometrial Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometrial Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of a Weight Loss Intervention in People With Endometrial Cancer
RECRUITING · Early Phase 1
-
A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer
RECRUITING · Early Phase 1
-
A Pre-Op Window Study Evaluating Anti-Proliferative Effects of Atorvastatin on the Endometrium
COMPLETED · Early Phase 1
-
Evaluation of the Molecular Effects of Metformin on the Endometrium in Patients With Endometrial Cancer
COMPLETED · Early Phase 1
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
The Better, Harder, Faster, Stronger Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI